To see, to know, to heal .    

Declare the past,
diagnose the present,
foretell the future (Hippocrates)

Seeing is the

About us


The name photonamic consists of photo (= light) and dynamics and thus represents the field of activity of photonamic GmbH & Co. KG ("photonamic"). The effect of light on certain molecules is manifold and ultimately leads not only to coloration, but can also lead to fluorescence or initiation of chemical reactions.
Photonamic takes advantage of these dynamics of light by using a specific molecule that is metabolized into a photosensitizer in cells or in cell assemblies or in the body. Depending on the choice of wavelength, this can lead to a wide variety of effects triggered by the light. The use of light and the application of photosensitizers is not really a new principle, but has been known and researched for decades.
photonamic has set itself the goal of researching and developing these possibilities in a targeted manner in order to derive diverse applications from them. Unlike many other approaches, the molecule primarily used by photonamic is a precursor of the actual photosensitizer, which is metabolically converted into the light-excitable molecule and exhibits the corresponding photodyna-mic properties. The resulting fascinating applications in imaging and also therapy form the core of photonamic's activities.
Through numerous collaborations and projects with partner companies, academic institutions for clinical applicability and also with corresponding equipment companies for light sources, sensors and camera systems, the diversity of these technologies can be imagined.


‍"NX Development Corp. ls Granted Orphan Drug Designation Status by US FDA for Gleolan® in Ovarian and Related Cancers"

Lexington, KY, March 5, 2024 -NX Development Corp. (NXDC) has achieved another
milestone as we proudly announce the recent granting of orphan-drug status by the U.S. Food
and Drug Administration (FDA) for Gleolan (aminolevulinic acid HCl). This designation was
provided for the "real-time detection and visualization of epithelial ovarian tumors during
debulking surgery."
Dr. Salvatore DeSena, CEO of NX Development Corp., shared this excitement, stating, "On
behalf of our entire team, I am proud to announce that NX Development Corp. secured orphan-
drug status for Gleolan in ovarian, fallopian tube, and primary peritoneal cancer. This
achievement demonstrates NXDC's commitment to exploring new and innovative uses for
Gleolan to help patients and surgeons in their fight against these cancers.

"This important milestone underlines the capabilities of aminolevulinic acid HCl in fluorescence-
guided surgery. As a group we aim to expand this further, also to other countries as well,
providing support to patients and healthcare professionals combating cancer globally", said Dr.
Ulrich Kosciessa, Chairman of the Board of NXDC and CEO of photonamic GmbH & Co KG.
(Pinneberg, Germany) parent company to NXDC.


"First Patient Enrolled in OVA-302 Study After FDA Orphan Designation for Gleolan®"....more


All press articles